C12Y 301/21004
Type ii site-specific deoxyribonuclease
Official title: Type II site-specific deoxyribonuclease (3.1.21.4)
C12Y301/21004 (Type ii site-specific deoxyribonuclease) appears on 135 US grants and 237 published applications in this corpus.
Search patents in C12Y- Granted patents
- 135
- Published applications
- 237
- Assignees
- 84
- Inventors
- 258
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 3 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 1 | 2 |
| 2011 | 1 | 8 |
| 2012 | 1 | 15 |
| 2013 | 7 | 7 |
| 2014 | 9 | 20 |
| 2015 | 7 | 9 |
| 2016 | 13 | 26 |
| 2017 | 10 | 23 |
| 2018 | 11 | 19 |
| 2019 | 13 | 11 |
| 2020 | 17 | 22 |
| 2021 | 8 | 11 |
| 2022 | 14 | 15 |
| 2023 | 7 | 7 |
| 2024 | 9 | 10 |
| 2025 | 3 | 12 |
| 2026 | 4 | 15 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Variants of CRISPR from Prevotella and Francisella 1 (Cpf1)9 Jun 2026US 12,649,913 B2The General Hospital Corporation
- Mitochondrial genome editing methods28 Apr 2026US 12,612,617 B2Mayo Foundation for Medical Education and Research
- Variants of CRISPR from Prevotella and Francisella 1 (Cpf1)31 Mar 2026US 12,590,299 B2The General Hospital Corporation
- Protected guide RNAs (pgRNAs)10 Mar 2026US 12,571,005 B2Massachusetts Institute of Technology
- Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants27 May 2025US 12,312,613 B2The General Hospital Corporation
- Fusion proteins and applications thereof20 Aug 2026US 2026/0242761 A1Guangzhou Reforgene Medicine Co., Ltd.
- Compositions targeting klkb1 and methods of use thereof13 Aug 2026US 2026/0232843 A1Poseida Therapeutics, Inc.
- Nucleobase editor systems and methods of use thereof23 Jul 2026US 2026/0207779 A1Peking University
- Method for constructing host strain capable of highly expressing human serum albumin23 Jul 2026US 2026/0209784 A1Hebei Huakai Huihe Biomedical Co., Ltd.
- Synthetic single-stranded dna molecules and methods of producing and using the same16 Jul 2026US 2026/0199386 A1Generation Bio Co.
Most cited
By later US patents
- DNA-binding proteins and uses thereof217US 8,586,526 B2Sangamo BioSciences, Inc. · 2013
- TAL effector-mediated DNA modification216US 8,440,431 B2Iowa State University Research Foundation, Inc. · 2013
- Tal effector-mediated DNA modification187US 8,440,432 B2Iowa State University Research Foundation, Inc. · 2013
- TAL effector-mediated DNA modification186US 8,450,471 B2Iowa State University Research Foundation, Inc. · 2013
- Methods and compositions for targeted cleavage and recombination184US 7,888,121 B2Sangamo BioSciences, Inc. · 2011